Review Articles
Regression of Atherosclerosis: Where are We Now, and Where are We Going?
Authors:
Venkateshwar R. Polsani ,
Methodist DeBakey Heart & Vascular Center, Houston, Texas, US
About Venkateshwar R.
M.D.
Christie M. Ballantyne
Methodist DeBakey Heart & Vascular Center, Houston, Texas, US
About Christie M.
M.D.
Abstract
Atherosclerosis is a chronic inflammatory disorder, and lipoproteins are believed to play a critical role in its initiation and progression. Increased levels of atherogenic lipoproteins (low-density lipoprotein [LDL], intermediate-density lipoprotein [IDL], very-low-density lipoprotein [VLDL] remnants, lipoprotein(a) [Lp(a)]), which all contain apolipoprotein (apo) B, are associated with increased development and progression of atherosclerosis. In contrast, high levels of high-density lipoprotein (HDL) are associated with less atherosclerosis, and HDL is thought to play a critical role in reverse cholesterol transport. Therapies that alter lipoprotein metabolism can affect the progression, stabilization, and regression of atherosclerosis, and these effects can be studied by a number of imaging modalities.
How to Cite:
1. Polsani VR, Ballantyne CM. Regression of Atherosclerosis: Where are We Now, and Where are We Going?. Methodist DeBakey Cardiovascular Journal. 2008;4(4):18-21. DOI: http://doi.org/10.14797/mdcvj.141
Published on
01 Jan 2008.
Peer Reviewed
Downloads
